Mylan Can't Get Top Court Review Of $76M Antitrust Ruling
The U.S. Supreme Court on Monday declined to hear Mylan Laboratories Inc.'s appeal of a $76 million antitrust verdict over licensing agreements for anti-anxiety medications based on Mylan's claims that the...To view the full article, register now.
Already a subscriber? Click here to view full article